Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Global Blood Therapeutics, Inc.GBT · Entity 123220 | See Remarks | February 14, 2018 | February 16, 2018 |
| Mirum Pharmaceuticals, Inc.MIRM · Entity 2416 | PRESIDENT AND COO | June 05, 2026 | June 08, 2026 |
| Rain Oncology Inc.RAIN · Entity 94695 | Director | January 26, 2024 | January 26, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Global Blood Therapeutics, Inc.
Report date February 14, 2018 · Filed February 16, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,627 |
Reported balance
After 2018-02-14 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2018-02-14 · Exercise / conversion · Acquired 1,600 · Balance 9,627 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F2: Includes 661 shares acquired under the Issuer's Employee Stock Purchase Plan ("ESPP") on July 31, 2017 and 549 shares acquired under the ESPP on January 31, 2018, each in a transaction exempt under Rule 16b-3. |
| Common StockSEC Table I · non-derivative | Direct | 8,833 |
Reported balance
After 2018-02-14 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2018-02-14 · Tax withholding · Disposed 794 · Balance 8,833 F3: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 1,600 shares of Common Stock underlying the Reporting Person's RSUs. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 5,600 |
Reported balance
After 2018-02-14 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2018-02-14 · Exercise / conversion · Disposed 1,600 · Balance 5,600 F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock. F4: On August 11, 2017, the Reporting Person was granted 12,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On February 14, 2018, one of the performance milestones was achieved, resulting in the vesting of 1,600 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Issuer's Common Stock.
F2: Includes 661 shares acquired under the Issuer's Employee Stock Purchase Plan ("ESPP") on July 31, 2017 and 549 shares acquired under the ESPP on January 31, 2018, each in a transaction exempt under Rule 16b-3.
F3: Represents number of shares of Issuer's Common Stock withheld to satisfy the Reporting Person's tax obligations in connection with the vesting of 1,600 shares of Common Stock underlying the Reporting Person's RSUs.
F4: On August 11, 2017, the Reporting Person was granted 12,000 RSUs, which vest in installments upon the achievement of specified market capitalization milestones of the Issuer on or before December 31, 2019, so long as the Reporting Person continues as an employee or other service provider of the Issuer through each vesting milestone. On February 14, 2018, one of the performance milestones was achieved, resulting in the vesting of 1,600 shares of Common Stock underlying the RSU grant. The RSUs are subject to accelerated vesting upon termination without cause or resignation for good reason after a change of control of the Issuer.
Mirum Pharmaceuticals, Inc.
Report date June 05, 2026 · Filed June 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 57,260 |
Reported balance
After 2026-06-05 transaction · row 1
1 source rowRow 1 · 2026-06-05 · Exercise / conversion · Acquired 16,988 · Balance 57,260 |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.19 · Expires 2031-01-06 | Direct | 48,012 |
Reported balance
After 2026-06-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-05 · Exercise / conversion · Disposed 16,988 · Balance 48,012 F1: The stock option is fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option is fully vested.
Rain Oncology Inc.
Report date January 26, 2024 · Filed January 26, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $0.001 per shareSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 1
1 source rowRow 1 · 2024-01-26 · Other · Disposed 8,796 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.95 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-01-26 · Disposition to issuer · Disposed 13,890 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.13 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-01-26 · Disposition to issuer · Disposed 42,596 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.21 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-01-26 · Disposition to issuer · Disposed 35,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.44 | Direct | 0 |
Reported balance
After 2024-01-26 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-01-26 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right.
F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 05, 2026 Filed Jun 8, 2026 20:27 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionStock Option (right to buy) · Derivative | 16,988 | $0.00 Strike: $19.19 | $0.00 |
DisclosureSEC source: 0001650131-26-000011 · form4-06082026_080628.xml · derivative · entry 2 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 48,012 Underlying: Common Stock · 16,988 shares Expires 2031-01-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| June 05, 2026 Filed Jun 8, 2026 20:27 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 16,988 | $19.19 | $325,999.72 |
DisclosureSEC source: 0001650131-26-000011 · form4-06082026_080628.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,260 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 16, 2026 Filed Mar 17, 2026 23:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 16,515 | $91.98 | $1,519,015.02 |
DisclosureSEC source: 0001650131-26-000010 · form4-03172026_070307.xml · nonDerivative · entry 3 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,272 F2 · kind: Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 23:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 23,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001650131-26-000010 · form4-03172026_070307.xml · derivative · entry 5 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 23,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: The shares vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027. F4 · derivative.expiration_date: The shares vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 23:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 7,220 | $0.00 | $0.00 |
DisclosureSEC source: 0001650131-26-000010 · form4-03172026_070307.xml · derivative · entry 4 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 7,220 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares vest as follows: 2/3 of the shares vest on March 15, 2025 and 1/3 of the shares vest on March 15, 2026. F3 · derivative.expiration_date: The shares vest as follows: 2/3 of the shares vest on March 15, 2025 and 1/3 of the shares vest on March 15, 2026. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 23:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 23,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001650131-26-000010 · form4-03172026_070307.xml · nonDerivative · entry 2 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 56,787 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 15, 2026 Filed Mar 17, 2026 23:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 7,220 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001650131-26-000010 · form4-03172026_070307.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,787 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 06, 2026 Filed Mar 11, 2026 20:05 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionStock Option (right to buy) · Derivative | 5,912 | $0.00 Strike: $15.87 | $0.00 |
DisclosureSEC source: 0001650131-26-000008 · form4-03112026_080315.xml · derivative · entry 2 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,088 Underlying: Common Stock · 5,912 shares Expires 2032-01-05 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option is fully vested. Read SEC document |
| March 06, 2026 Filed Mar 11, 2026 20:05 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 5,912 | $15.87 | $93,823.44 |
DisclosureSEC source: 0001650131-26-000008 · form4-03112026_080315.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,567 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2026 Filed Feb 4, 2026 02:45 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 2,631 | $103.30 | $271,791.51 |
DisclosureSEC source: 0001650131-26-000007 · form4-02032026_090206.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,655 F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| January 28, 2026 Filed Jan 30, 2026 23:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantPerformance Restricted Stock Units · Derivative | 34,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001650131-26-000005 · form4-01302026_060103.xml · derivative · entry 3 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,500 Underlying: Common Stock · 34,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: On January 23, 2024, the reporting person was granted performance restricted stock units ("PSUs") which vest upon satisfaction of certain performance criteria. On January 28, 2026, performance criteria were determined to have been met. The shares subject to the PSUs vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027. F4 · derivative.expiration_date: On January 23, 2024, the reporting person was granted performance restricted stock units ("PSUs") which vest upon satisfaction of certain performance criteria. On January 28, 2026, performance criteria were determined to have been met. The shares subject to the PSUs vest as follows: 2/3 of the shares vest on March 15, 2026 and 1/3 of the shares vest on March 15, 2027. Read SEC document |
| January 28, 2026 Filed Jan 30, 2026 23:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantRestricted Stock Units · Derivative | 16,280 | $0.00 | $0.00 |
DisclosureSEC source: 0001650131-26-000005 · form4-01302026_060103.xml · derivative · entry 2 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,280 Underlying: Common Stock · 16,280 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 28, 2026 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 28, 2026 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document |
| January 28, 2026 Filed Jan 30, 2026 23:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 25,120 | $0.00 Strike: $100.85 | $0.00 |
DisclosureSEC source: 0001650131-26-000005 · form4-01302026_060103.xml · derivative · entry 1 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,120 Underlying: Common Stock · 25,120 shares Expires 2036-01-27 F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 28, 2026 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| January 26, 2026 Filed Jan 27, 2026 21:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 3,143 | $96.19 | $302,331.46 |
DisclosureSEC source: 0001650131-26-000003 · form4-01272026_040106.xml · nonDerivative · entry 2 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,286 F2 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 21:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionRestricted Stock Units · Derivative | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001650131-26-000003 · form4-01272026_040106.xml · derivative · entry 3 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,750 Underlying: Common Stock · 5,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document |
| January 23, 2026 Filed Jan 27, 2026 21:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 5,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001650131-26-000003 · form4-01272026_040106.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,429 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Read SEC document |
| January 22, 2026 Filed Jan 23, 2026 22:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 2,382 | $93.33 | $222,300.63 |
DisclosureSEC source: 0001650131-26-000002 · form4-01232026_050104.xml · nonDerivative · entry 2 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,679 F3 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 22:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionRestricted Stock Units · Derivative | 4,167 | $0.00 | $0.00 |
DisclosureSEC source: 0001650131-26-000002 · form4-01232026_050104.xml · derivative · entry 3 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,333 Underlying: Common Stock · 4,167 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F4 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 21, 2025 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. F4 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 21, 2025 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document |
| January 21, 2026 Filed Jan 23, 2026 22:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 4,167 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001650131-26-000002 · form4-01232026_050104.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,061 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F2 · balance_after: Includes 222 shares of common stock that were acquired by the Reporting Person on November 10, 2025, pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| March 17, 2025 Filed Mar 19, 2025 01:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 7,879 | $44.21 | $348,364.47 |
DisclosureSEC source: 0001415889-25-008557 · form4-03182025_090304.xml · nonDerivative · entry 2 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,672 F2 · kind: Shares sold to cover tax withholding obligations associated with the vesting of the performance restricted stock units. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 01:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionPerformance Restricted Stock Units · Derivative | 14,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-008557 · form4-03182025_090304.xml · derivative · entry 3 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,220 Underlying: Common Stock · 14,440 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The shares vest as follows: 2/3 of the shares vest on March 15, 2025 and 1/3 of the shares vest on March 15, 2026. F3 · derivative.expiration_date: The shares vest as follows: 2/3 of the shares vest on March 15, 2025 and 1/3 of the shares vest on March 15, 2026. Read SEC document |
| March 15, 2025 Filed Mar 19, 2025 01:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 14,440 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-008557 · form4-03182025_090304.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each performance restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 21:28 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 1,169 | $45.74 | $53,470.06 |
DisclosureSEC source: 0001415889-25-006955 · form4-03052025_090314.xml · nonDerivative · entry 2 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,111 Read SEC document |
| March 04, 2025 Filed Mar 5, 2025 21:28 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 13,681 | $45.57 | $623,458.22 |
DisclosureSEC source: 0001415889-25-006955 · form4-03052025_090314.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,280 F1 · price: The weighted average sale price for the transaction reported was $45.571143, and the range of prices were between $45.50 and $45.88. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 03, 2025 Filed Feb 4, 2025 22:30 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 2,627 | $48.22 | $126,680.77 |
DisclosureSEC source: 0001415889-25-002982 · form4-02042025_050206.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,961 F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| January 24, 2025 Filed Jan 27, 2025 21:50 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 3,177 | $47.92 | $152,256.14 |
DisclosureSEC source: 0001415889-25-002137 · form4-01272025_090133.xml · nonDerivative · entry 2 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,588 F2 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:50 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionRestricted Stock Units · Derivative | 5,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-002137 · form4-01272025_090133.xml · derivative · entry 3 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,500 Underlying: Common Stock · 5,750 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document |
| January 23, 2025 Filed Jan 27, 2025 21:50 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | Exercise / conversionCommon Stock | 5,750 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001415889-25-002137 · form4-01272025_090133.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,765 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of common stock (or its cash equivalent, at the discretion of the Issuer). Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 22:51 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantPerformance Restricted Stock Units · Derivative | 21,660 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001952 · form4-01232025_100138.xml · derivative · entry 3 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,660 Underlying: Common Stock · 21,660 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F4 · derivative.exercise_date: On January 31, 2023, the reporting person was granted performance restricted stock units ("PSUs") which vest upon satisfaction of certain performance criteria. On January 21, 2025, performance criteria were determined to have been met. The shares subject to the PSUs vest as follows: 2/3 of the shares vest on March 15, 2025 and 1/3 of the shares vest on March 15, 2026. F4 · derivative.expiration_date: On January 31, 2023, the reporting person was granted performance restricted stock units ("PSUs") which vest upon satisfaction of certain performance criteria. On January 21, 2025, performance criteria were determined to have been met. The shares subject to the PSUs vest as follows: 2/3 of the shares vest on March 15, 2025 and 1/3 of the shares vest on March 15, 2026. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 22:51 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantRestricted Stock Units · Derivative | 12,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-001952 · form4-01232025_100138.xml · derivative · entry 2 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,500 Underlying: Common Stock · 12,500 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 21, 2025 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 21, 2025 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document |
| January 21, 2025 Filed Jan 23, 2025 22:51 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $47.98 | $0.00 |
DisclosureSEC source: 0001415889-25-001952 · form4-01232025_100138.xml · derivative · entry 1 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2035-01-20 F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 21, 2025 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| January 07, 2025 Filed Jan 8, 2025 21:44 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 1,998 | $42.82 | $85,544.97 |
DisclosureSEC source: 0001415889-25-001144 · form4-01082025_090118.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,015 F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| March 25, 2024 Filed Mar 25, 2024 21:41 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 4,303 | $25.80 | $111,017.40 |
DisclosureSEC source: 0001415889-24-009046 · form4-03252024_090335.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,013 F1 · price: The weighted average sale price for the transaction reported was $25.80, and the range of prices were between $25.80 and $25.825. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided. Read SEC document |
| February 02, 2024 Filed Feb 6, 2024 02:05 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 1,790 | $26.19 | $46,883.14 |
DisclosureSEC source: 0001415889-24-002755 · form4-02062024_020222.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,695 F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:49 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $2.44 | Not disclosed |
DisclosureSEC source: 0001999371-24-000974 · ownership.xml · derivative · entry 5 Radovich Peter · CIK 0001650131 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:49 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 35,000 | Not disclosed Strike: $1.21 | Not disclosed |
DisclosureSEC source: 0001999371-24-000974 · ownership.xml · derivative · entry 4 Radovich Peter · CIK 0001650131 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:49 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 42,596 | Not disclosed Strike: $3.13 | Not disclosed |
DisclosureSEC source: 0001999371-24-000974 · ownership.xml · derivative · entry 3 Radovich Peter · CIK 0001650131 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 42,596 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:49 UTC | Rain Oncology Inc. RAIN · Entity 94695 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,890 | Not disclosed Strike: $3.95 | Not disclosed |
DisclosureSEC source: 0001999371-24-000974 · ownership.xml · derivative · entry 2 Radovich Peter · CIK 0001650131 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,890 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under the Issuer's Amended and Restated 2018 Stock Option/Stock Issuance Plan or the Issuer's 2021 Equity Incentive Plan, pursuant to any inducement award or otherwise that was outstanding immediately prior to the Effective Time was cancelled for no consideration. Read SEC document |
| January 26, 2024 Filed Jan 26, 2024 16:49 UTC | Rain Oncology Inc. RAIN · Entity 94695 | OtherCommon Stock, par value $0.001 per share | 8,796 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001999371-24-000974 · ownership.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · kind: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right. F1 · shares: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right. F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right. F1 · acquired: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Pathos AI, Inc. ("Parent") and WK Merger Sub, Inc., a wholly owned subsidiary of Parent ("Merger Sub"), dated as of December 13, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for all of the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer effective as of January 26, 2024 (the "Effective Time"). Pursuant to the terms of the Merger Agreement, at the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $1.16 in cash without interest, plus (ii) one contingent value right. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 00:10 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantRestricted Stock Units · Derivative | 17,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001823 · form4-01252024_070101.xml · derivative · entry 2 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,250 Underlying: Common Stock · 17,250 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. F3 · derivative.expiration_date: 1/3rd of the shares subject to the restricted stock units shall vest on each anniversary of January 23, 2024 (the "Vesting Commencement Date"), such that the entire award will be vested on the three-year anniversary of the Vesting Commencement Date. Read SEC document |
| January 23, 2024 Filed Jan 26, 2024 00:10 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 70,000 | $0.00 Strike: $26.49 | $0.00 |
DisclosureSEC source: 0001415889-24-001823 · form4-01252024_070101.xml · derivative · entry 1 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2034-01-22 F1 · derivative.exercise_date: 1/4th of the shares vest one year after January 23, 2024 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| January 08, 2024 Filed Jan 10, 2024 01:28 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 1,408 | $28.03 | $39,472.58 |
DisclosureSEC source: 0001415889-24-000884 · form4-01102024_010106.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · CHIEF OPERATING OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,485 F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| November 10, 2023 Filed Nov 16, 2023 01:11 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 218 | $22.29 | $4,858.57 |
DisclosureSEC source: 0001209191-23-055433 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,893 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 218 shares by the Reporting Person on November 10, 2023 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 21:12 UTC | Rain Oncology Inc. RAIN · Entity 94695 | GrantStock Option (Right to Buy) · Derivative | 35,000 | $0.00 Strike: $1.21 | $0.00 |
DisclosureSEC source: 0001104659-23-090703 · tm2323614-7_4seq1.xml · derivative · entry 1 Radovich Peter · CIK 0001650131 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires 2033-08-09 F1 · derivative.exercise_date: This option represents a right to purchase a total of 35,000 shares of the Issuer's common stock, which will vest in full on the date of the 2024 Annual Meeting of Stockholders of the Issuer, subject to the Reporting Person's continued service to the Issuer. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 23:47 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 1,425 | $25.65 | $36,546.41 |
DisclosureSEC source: 0001209191-23-041344 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,675 F1 · kind: Shares sold to cover tax withholding obligations associated with the vesting of restricted stock units. Read SEC document |
| May 10, 2023 Filed May 19, 2023 20:05 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 968 | $16.92 | $16,381.95 |
DisclosureSEC source: 0001209191-23-030964 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,100 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 968 shares by the Reporting Person on May 10, 2023 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 22:41 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantStock Option (right to buy) · Derivative | 57,750 | $0.00 Strike: $23.48 | $0.00 |
DisclosureSEC source: 0001209191-23-006302 · doc4.xml · derivative · entry 2 Radovich Peter · CIK 0001650131 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,750 Underlying: Common Stock · 57,750 shares Expires 2033-01-30 F2 · derivative.exercise_date: 1/4th of the shares vest one year after January 31, 2023 (the "Vesting Commencement Date") and the balance of the shares vest in a series of 36 successive equal monthly installments measured from the first anniversary of the Vesting Commencement Date. Read SEC document |
| January 31, 2023 Filed Feb 2, 2023 22:41 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 14,440 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-006302 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,132 F1 · shares: Represents restricted stock unit award granted under the Issuer's 2019 Equity Incentive Plan. Read SEC document |
| January 09, 2023 Filed Mar 18, 2024 21:46 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | SaleCommon Stock | 1,379 | $20.62 | $28,438.15 |
DisclosureSEC source: 0001415889-24-008322 · form4-03182024_090306.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · PRESIDENT AND COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,316 F1 · kind: Shares sold to cover tax witholding obligations associated with the vesting of restricted stock units. Read SEC document |
| November 10, 2022 Filed Nov 15, 2022 02:41 UTC | Mirum Pharmaceuticals, Inc. MIRM · Entity 2416 | GrantCommon Stock | 292 | $17.05 | $4,978.89 |
DisclosureSEC source: 0001209191-22-056888 · doc4.xml · nonDerivative · entry 1 Radovich Peter · CIK 0001650131 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,692 F1 · kind: This Form 4 is being filed voluntarily to report the acquisition of 292 shares by the Reporting Person on November 10, 2022 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.